ESCO Technologies Inc. — FY2013 Form 10-K
Reporting period: Fiscal year ended September 30, 2013. This is an annual filing, not a separate fourth-quarter report. ESCO supplies engineered products and systems for utility, industrial, aerospace, and commercial markets. Its continuing operations comprised Filtration, RF Shielding and Test, and Utility Solutions; Aclara was reported as discontinued operations and held for sale.
Financial performance and position
- Revenue: The supplied filing text does not provide consolidated revenue or a clear year-over-year revenue-growth figure. It states international sales from continuing operations were approximately $154 million, or 31% of revenue, versus $162 million (34%) in FY2012 and $132 million (29%) in FY2011.
- Segment mix: Filtration represented approximately 44% of total revenue in FY2013, compared with 41% in FY2012; Test represented 34%, compared with 37%. Doble products and services represented approximately 22% of total revenue, compared with 23%. The filing’s incorporated financial statements and segment note should be consulted for the precise basis and dollar amounts.
- Profit, margins, and cash flow: The supplied text does not give clear consolidated operating income, net income, EPS, margins, or cash-flow amounts. It references the 2013 Annual Report for the financial statements and management’s discussion.
- Backlog: Continuing-operations firm orders were $272.1 million at September 30, 2013, up $26.5 million (11%) from $245.6 million at the start of the year. Filtration backlog was $157.7 million, Test $90.4 million, and Utility Solutions $24.0 million. Approximately 72% was expected to be completed in FY2014.
- Liquidity and debt: At year-end, ESCO had approximately $43 million in cash, $172 million of borrowings under its $450 million revolving facility, and $13 million of letters of credit. It reported approximately $265 million available to borrow, plus a potential $250 million facility increase subject to lender acceptance. The facility matures May 14, 2017; ESCO stated it complied with all debt covenants.
- Research and development: Continuing-operations company-sponsored R&D was approximately $12.7 million in FY2013, versus $14.3 million in FY2012; customer-sponsored R&D was $15.0 million, versus $9.2 million.
Material changes and unusual items
- In the third quarter, the board approved a process to sell Aclara. Aclara was classified as discontinued operations and held for sale for all periods presented, with prior periods restated. The filing says Aclara incurred an operating loss in FY2013 and that its carrying value was significantly written down in the fourth quarter; the amount of the write-down is not stated in the supplied text. A further impairment could arise if sale proceeds fall below carrying value.
- ESCO acquired Canyon for $9.2 million in cash and its manufacturing facility for $7 million; it planned to consolidate Crissair operations into Canyon’s facility during FY2014. The filing also describes acquisitions of Finepoint ($2.5 million), Felix Tool ($1.2 million), and Metrum ($25 million plus contingent consideration). Metrum became part of Aclara and thus discontinued operations.
- The company consolidated domestic Test manufacturing facilities, closing one site, and substantially completed the closure of Doble Lemke in Germany. Aclara separately planned to outsource RF AMI manufacturing from its Solon, Ohio facility.
- ESCO did not repurchase common shares during FY2013’s fourth quarter.
Outlook, risks, and contingencies
- The filing refers to FY2014 revenue growth and EPS guidance, but the supplied text does not provide clear numerical guidance. Those figures are in the incorporated 2013 Annual Report.
- Management identified uncertainty over whether Aclara could be sold promptly and on acceptable terms, the potential for additional impairment, and uncertainty about the effects of a completed sale on credit-facility availability and covenants.
- Key risks include economic weakness and customer spending, international exposure and currency changes, competition, government funding and contract termination, reliance on sole- or limited-source suppliers, raw-material availability and cost, product-development execution, and facility-consolidation costs and disruption.
- Other risks include contract/project cost overruns, product defects and recalls, software and goodwill impairment, inventory obsolescence, environmental compliance and remediation, and litigation. Management stated that known environmental matters were not expected to materially adversely affect financial condition or results, while noting substantial estimation uncertainty. It also considered ordinary-course claims adequately reserved, insured, or not likely to be material.
Important facts for investors to verify
- Review the incorporated 2013 Annual Report for complete FY2013 and FY2012 revenue, earnings, EPS, margins, cash flows, segment results, and the amount and accounting treatment of Aclara’s impairment.
- Check the status, proceeds, timing, and any additional impairment associated with the Aclara sale process, as well as the final treatment of its results.
- Verify the numerical FY2014 revenue and EPS outlook, including any adjusted-EPS definition and assumptions.
- Assess debt covenants, actual revolver availability, and any impact of an Aclara transaction on liquidity and borrowing capacity.
- Track execution costs and expected savings from the Crissair/Canyon consolidation and other facility or manufacturing changes.